Ferroptosis and metabolic dysfunction-associated fatty liver disease: Is there a link?

被引:44
|
作者
Feng, Gong [1 ]
Byrne, Christopher D. [2 ]
Targher, Giovanni [3 ,4 ]
Wang, Fudi [5 ,6 ]
Zheng, Ming-Hua [7 ,8 ,9 ]
机构
[1] Xian Med Univ, Xian, Peoples R China
[2] Univ Hosp Southampton, Southampton Gen Hosp, Southampton Natl Inst Hlth Res Biomed Res Ctr, Southampton, Hants, England
[3] Univ Verona, Dept Med, Sect Endocrinol Diabet & Metab, Verona, Italy
[4] Azienda Osped Univ Integrata Verona, Verona, Italy
[5] Zhejiang Univ, Affiliated Hosp 4, Sch Publ Hlth, Sch Med, Hangzhou, Peoples R China
[6] Univ South China, Affiliated Hosp 1, Sch Publ Hlth, Hengyang Med Sch,Basic Med Sci, Hengyang, Peoples R China
[7] Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatol, NAFLD Res Ctr, 2 Fuxue Lane, Wenzhou 325000, Peoples R China
[8] Wenzhou Med Univ, Inst Hepatol, Wenzhou, Peoples R China
[9] Key Lab Diag & Treatment Dev Chron Liver Dis Zhej, Wenzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
ferroptosis; MAFLD; metabolic syndrome; pathogenesis; type; 2; diabetes; OXIDATIVE STRESS; IRON-METABOLISM; CELL-DEATH; ACTIVATION; FIBROSIS; OBESITY;
D O I
10.1111/liv.15163
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD), recently re-defined and re-classified as metabolic dysfunction-associated fatty liver disease (MAFLD), has become increasingly prevalent and emerged as a public health problem worldwide. To date, the precise pathogenic mechanisms underpinning MAFLD are not entirely understood, and there is no effective pharmacological therapy for NAFLD/MAFLD. As a newly discovered form of iron-dependent programmed cell death, ferroptosis can be involved in the development and progression of various chronic diseases, but the pathogenic connections and mechanisms that link MAFLD and ferroptosis have not been fully elucidated. The main characteristics of ferroptosis are the accumulation of lipid peroxides and reactive oxygen species. In this brief narrative review, the mechanisms of ferroptosis and its putative pathogenic role in MAFLD are discussed to highlight potential new research directions and ideas for the prevention and treatment of MAFLD.
引用
收藏
页码:1496 / 1502
页数:7
相关论文
共 50 条
  • [1] Puerarin ameliorates metabolic dysfunction-associated fatty liver disease by inhibiting ferroptosis and inflammation
    Yang, Mengmeng
    Xia, Longqing
    Song, Jia
    Hu, Huiqing
    Zang, Nan
    Yang, Jingwen
    Zou, Ying
    Wang, Liming
    Zheng, Xiaoyue
    He, Qin
    Liu, Jidong
    Liu, Fuqiang
    Liang, Kai
    Sun, Lei
    Chen, Li
    [J]. LIPIDS IN HEALTH AND DISEASE, 2023, 22 (01)
  • [2] Puerarin ameliorates metabolic dysfunction-associated fatty liver disease by inhibiting ferroptosis and inflammation
    Mengmeng Yang
    Longqing Xia
    Jia Song
    Huiqing Hu
    Nan Zang
    Jingwen Yang
    Ying Zou
    Liming Wang
    Xiaoyue Zheng
    Qin He
    Jidong Liu
    Fuqiang Liu
    Kai Liang
    Lei Sun
    Li Chen
    [J]. Lipids in Health and Disease, 22
  • [4] Diabetes and metabolic dysfunction-associated fatty liver disease
    Davis, Timothy M. E.
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 123
  • [5] LIVER FIBROSIS IN ASIANS WITH METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE
    Kim, Byung Ik
    Sohn, Won
    Kwon, Heon-Ju
    Cho, Yong Kyun
    [J]. HEPATOLOGY, 2021, 74 : 1022A - 1022A
  • [6] Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease
    Sohn, Won
    Kwon, Heon-Ju
    Chang, Yoosoo
    Ryu, Seungho
    Cho, Yong Kyun
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (05) : E1135 - E1148
  • [7] Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
    Bhopale, Kamlesh K.
    Srinivasan, Mukund P.
    [J]. LIVERS, 2023, 3 (04): : 597 - 617
  • [8] Therapeutic developments in metabolic dysfunction-associated fatty liver disease
    Shi Yiwen
    Fan Jiangao
    [J]. 中华医学杂志(英文版), 2022, (09) : 1009 - 1018
  • [9] Therapeutic developments in metabolic dysfunction-associated fatty liver disease
    Shi, Yiwen
    Fan, Jiangao
    [J]. CHINESE MEDICAL JOURNAL, 2022, 135 (09) : 1009 - 1018
  • [10] Metabolic dysfunction-associated fatty liver disease: a year in review
    Alharthi, Jawaher
    Gastaldelli, Amalia
    Cua, Ian Homer
    Ghazinian, Hasmik
    Eslam, Mohammed
    [J]. CURRENT OPINION IN GASTROENTEROLOGY, 2022, 38 (03) : 251 - 260